Anbio Biotechnology Class A Ordinary Shares
NNNN
Rank in Stocks
#17433
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main,... Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Share Price
$3.82
Last synced: 2026-11-13
Market Cap
$167.66M
Change (1 day)
0.53%
Change (1 year)
-85.98%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Anbio Biotechnology Class A Ordinary Shares (NNNN)
Category
Healthcare
EPS for Anbio Biotechnology Class A Ordinary Shares (NNNN)
EPS as of December 2025 TTM: $0.24
According to Anbio Biotechnology Class A Ordinary Shares's latest financial reports, its current EPS (TTM) is $0.24. At the end of 2025 the company had an EPS of $0.16, an increase over its 2024 EPS of $0.06.
EPS history for Anbio Biotechnology Class A Ordinary Shares from 2021 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.24 | 50.00% |
| 2025 | $0.16 | 185.71% |
| 2024 | $0.06 | 256.69% |
| 2023 | $0.02 | -77.44% |
| 2022 | $0.07 | 174.02% |
| 2021 | $0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $8.37 | 3,387.50% |
US
|
|
| $5.95 | 2,380.29% |
FR
|
|
| $4.15 | 1,629.17% |
US
|
|
| $5.26 | 2,091.42% |
JP
|
|
| $1.34 | 458.33% |
CH
|
Questions about Anbio Biotechnology Class A Ordinary Shares's earnings per share (EPS)
What is Anbio Biotechnology Class A Ordinary Shares's earnings per share (EPS)?
Anbio Biotechnology Class A Ordinary Shares's earnings per share (EPS) over the last twelve months is $0.24, as of Dec 2025.
What was Anbio Biotechnology Class A Ordinary Shares's earnings per share (EPS) in 2025?
In 2025, Anbio Biotechnology Class A Ordinary Shares's earnings per share (EPS) was $0.16, 166.67% more than in 2024 ($0.06).
How has Anbio Biotechnology Class A Ordinary Shares's earnings per share (EPS) changed since 2021?
From 2021 to 2025, Anbio Biotechnology Class A Ordinary Shares's earnings per share (EPS) went from $0.03 to $0.16, an average growth of 51.97% a year.
How does Anbio Biotechnology Class A Ordinary Shares's earnings per share (EPS) compare with similar companies?
Anbio Biotechnology Class A Ordinary Shares's earnings per share (EPS) ($0.24) is lower than that of all 5 similar companies listed above. The highest among them is Intuitive Surgical, Inc., with $8.37.